Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Merck & Co. has entered an exclusive licensing agreement with Taiho Pharmaceutical and Astex Pharmaceuticals for small-molecule cancer drugs that inhibit KRAS. Merck will pay the companies $50 million up front and up to $2.5 billion more depending on drug development and sales milestones. KRAS, one of the frequently mutated genes in cancer, has proved a challenging target for drug development. Taiho and Astex are both part of Japan’s Otsuka Pharmaceutical.
This article has been sent to the following recipient: